JP2016502083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502083A5 JP2016502083A5 JP2015544204A JP2015544204A JP2016502083A5 JP 2016502083 A5 JP2016502083 A5 JP 2016502083A5 JP 2015544204 A JP2015544204 A JP 2015544204A JP 2015544204 A JP2015544204 A JP 2015544204A JP 2016502083 A5 JP2016502083 A5 JP 2016502083A5
- Authority
- JP
- Japan
- Prior art keywords
- long
- treatment
- level
- tumor marker
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730900P | 2012-11-28 | 2012-11-28 | |
| US61/730,900 | 2012-11-28 | ||
| PCT/US2013/072205 WO2014085571A1 (en) | 2012-11-28 | 2013-11-27 | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502083A JP2016502083A (ja) | 2016-01-21 |
| JP2016502083A5 true JP2016502083A5 (OSRAM) | 2016-11-17 |
| JP6284541B2 JP6284541B2 (ja) | 2018-02-28 |
Family
ID=49753531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544204A Active JP6284541B2 (ja) | 2012-11-28 | 2013-11-27 | 長時間作用型トポイソメラーゼｉ阻害薬による乳癌治療の有効性を評価及び予測する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10132810B2 (OSRAM) |
| EP (1) | EP2926137B1 (OSRAM) |
| JP (1) | JP6284541B2 (OSRAM) |
| KR (1) | KR102120510B1 (OSRAM) |
| CN (1) | CN104813167B (OSRAM) |
| AU (1) | AU2013352223B2 (OSRAM) |
| CA (1) | CA2890082C (OSRAM) |
| ES (1) | ES2731725T3 (OSRAM) |
| MX (1) | MX366911B (OSRAM) |
| WO (1) | WO2014085571A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106191022B (zh) * | 2016-02-22 | 2019-08-20 | 叶尚勉 | 一种肿瘤特异抗原及其应用 |
| JP7546552B2 (ja) | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| CN112102914A (zh) * | 2020-09-25 | 2020-12-18 | 复旦大学附属肿瘤医院 | 曲妥珠单抗生物类似药的评价方法及系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| LT1675622T (lt) | 2003-09-17 | 2017-09-11 | Nektar Therapeutics | Daugiašakio polimero provaistai |
| CA2554779A1 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| WO2007025286A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| TWI426905B (zh) | 2006-02-09 | 2014-02-21 | Enzon Pharmaceuticals Inc | 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物 |
| US20110151580A1 (en) | 2007-11-06 | 2011-06-23 | University Health Network | Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient |
| AU2009297091B2 (en) * | 2008-09-23 | 2015-03-05 | Nektar Therapeutics | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
| AU2010321882B2 (en) | 2009-11-18 | 2016-01-14 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| WO2012031320A1 (en) * | 2010-09-06 | 2012-03-15 | Peter Maccallum Cancer Institute | Cancer diagnostic |
| US20140378404A1 (en) | 2011-10-25 | 2014-12-25 | Nektar Therapeutics | Treatment of Patients Suffering from Cancer |
-
2013
- 2013-11-27 MX MX2015006733A patent/MX366911B/es active IP Right Grant
- 2013-11-27 CA CA2890082A patent/CA2890082C/en active Active
- 2013-11-27 CN CN201380061709.6A patent/CN104813167B/zh active Active
- 2013-11-27 WO PCT/US2013/072205 patent/WO2014085571A1/en not_active Ceased
- 2013-11-27 US US14/648,042 patent/US10132810B2/en active Active
- 2013-11-27 KR KR1020157013659A patent/KR102120510B1/ko active Active
- 2013-11-27 AU AU2013352223A patent/AU2013352223B2/en active Active
- 2013-11-27 JP JP2015544204A patent/JP6284541B2/ja active Active
- 2013-11-27 EP EP13802833.7A patent/EP2926137B1/en active Active
- 2013-11-27 ES ES13802833T patent/ES2731725T3/es active Active
-
2018
- 2018-10-03 US US16/151,115 patent/US20190049450A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study | |
| Raman et al. | High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy | |
| Huang et al. | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area | |
| JP2018508469A5 (OSRAM) | ||
| JP2016533366A5 (OSRAM) | ||
| Robinson et al. | Progression-free survival as an end-point in solid tumours–perspectives from clinical trials and clinical practice | |
| Eskiizmir et al. | Nanomaterials: promising structures for the management of oral cancer | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| IL278423B2 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| RU2014119150A (ru) | Модулирование некоторых тирозинкиназ | |
| JP2016520528A5 (OSRAM) | ||
| Small Jr et al. | Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer | |
| Rivera-Valentin et al. | Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy | |
| RU2012107095A (ru) | ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF | |
| JP2016525097A5 (OSRAM) | ||
| JP2015511226A5 (OSRAM) | ||
| JP2019532047A5 (OSRAM) | ||
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| JP2016502083A5 (OSRAM) | ||
| JP2018522880A5 (OSRAM) | ||
| WO2013104050A3 (en) | Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor | |
| BR112014018374A8 (pt) | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica | |
| JP2019508408A5 (OSRAM) |